{"id":833420,"date":"2025-04-03T07:35:46","date_gmt":"2025-04-03T11:35:46","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/"},"modified":"2025-04-03T07:35:46","modified_gmt":"2025-04-03T11:35:46","slug":"trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/","title":{"rendered":"Trevi Therapeutics to Participate in Upcoming April Investor Conferences"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\"><br \/>\n          <span class=\"xn-location\">NEW HAVEN, Conn.<\/span><br \/>\n        <\/span>, <span class=\"legendSpanClass\"><span class=\"xn-chron\">April 3, 2025<\/span><\/span> \/PRNewswire\/ &#8212; <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4397658-1&amp;h=1469196983&amp;u=http%3A%2F%2Fwww.trevitherapeutics.com%2F&amp;a=Trevi+Therapeutics%2C+Inc.\" target=\"_blank\" rel=\"nofollow\">Trevi Therapeutics, Inc.<\/a>\u00a0(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC),\u00a0today announced that senior management will be participating in the following investor conferences in April.<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg\" title=\"Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto\/Trevi Therapeutics, Inc.)\" alt=\"Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto\/Trevi Therapeutics, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>\n        <b><br \/>\n          <u>24th Ann<\/u><br \/>\n        <\/b><br \/>\n        <b><br \/>\n          <u>ual Needham Virtual Healthcare Conference<br \/><\/u><br \/>\n        <\/b><br \/>\n        <span><br \/>\n          <span class=\"xn-chron\">April 7-10, 2025<\/span><br \/>\n          <br \/>\n        <\/span><br \/>\n        <b>Corporate Presentation<\/b>: <span class=\"xn-chron\">April 7<\/span>, <span class=\"xn-chron\">11:00-11:40 a.m. ET<\/span><br \/><b>Trevi Representatives:<\/b>\u00a0Jennifer Good, President and CEO, and Farrell Simon, CCO<br \/><a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4397658-1&amp;h=1185126235&amp;u=https%3A%2F%2Fwsw.com%2Fwebcast%2Fneedham146%2Fregister.aspx%3Fconf%3Dneedham146%26page%3Dtrvi%26url%3Dhttps%3A%2F%2Fwsw.com%2Fwebcast%2Fneedham146%2Ftrvi%2F2292897&amp;a=Register+here+to+watch+the+live+presentation.\" target=\"_blank\" rel=\"nofollow\">Register here to watch the live presentation.<\/a><\/p>\n<p>\n        <b><br \/>\n          <u>Jones Healthcare and Technology Innovation Conference<br \/><\/u><br \/>\n        <\/b><br \/>\n        <span><br \/>\n          <span class=\"xn-chron\">April 8-9, 2025<\/span>, <span class=\"xn-location\">Las Vegas, Nevada<\/span><br \/><\/span><br \/>\n        <b>Corporate Presentation<\/b>: <span class=\"xn-chron\">April 9<\/span>, <span class=\"xn-chron\">11:00-11:20 a.m. PT<\/span><br \/><b>Trevi Presenter:<\/b><span class=\"xn-person\">Jennifer Good<\/span>, President and CEO<br \/>Presentation available to in-person attendees.<\/p>\n<p>\n        <b><br \/>\n          <u>Piper Sandler Spring Biopharma Symposium<br \/><\/u><br \/>\n        <\/b><br \/>\n        <span class=\"xn-chron\">April 16-17, 2025<\/span>, <span class=\"xn-location\">Boston, Massachusetts<\/span><br \/><b>Trevi Representatives:<\/b>\u00a0Jennifer Good, President and CEO, and <span class=\"xn-person\">James Cassella<\/span>, CDO<\/p>\n<p>\n        <b>About Trevi Therapeutics, Inc.<br \/><\/b>Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine extended-release) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is the first and only therapy in clinical development to show a statistically significant reduction in chronic cough across patients with both IPF and RCC. Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), which are opioid receptors that play a key role in controlling cough hypersensitivity. Nalbuphine is not currently scheduled by the U.S. Drug Enforcement Agency.\u00a0\u00a0<\/p>\n<p>Chronic cough is a highly prevalent condition in IPF patients, impacting up to 85% of the IPF population. There are ~140,000 U.S. IPF patients and the impact of chronic cough is significant with patients coughing up to 1,500 times per day. This consistent cough and any associated damage may lead to worsening disease, a higher risk of progression, death, or need for lung transplant. Chronic cough also often leads to a decline in patients&#8217; social, physical, and psychological quality of life. There are no approved therapies for the treatment of chronic cough in patients with IPF and current off-label treatment options provide minimal benefit to patients.\u00a0<\/p>\n<p>Refractory chronic cough has no approved therapies in the U.S. and is defined as a persistent cough lasting &gt;8\u2005weeks despite treatment for an underlying condition (i.e., asthma, gastroesophageal reflux disease, non-asthmatic eosinophilic bronchitis, and upper airway cough syndrome or post-nasal drip) and includes unexplained chronic cough. RCC affects ~2-3 million patients in the U.S. and is caused by cough reflex hypersensitivity in both the central and peripheral nerves. It is a highly debilitating disease and accompanied by a wide range of complications, ranging from urinary incontinence in females to sleep disruption and social embarrassment that causes significant social and economic burdens for patients and those around them.<\/p>\n<p>Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.<\/p>\n<p>For more information, visit <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4397658-1&amp;h=701136241&amp;u=http%3A%2F%2Fwww.trevitherapeutics.com%2F&amp;a=www.TreviTherapeutics.com\" target=\"_blank\" rel=\"nofollow\">www.TreviTherapeutics.com<\/a>\u00a0and follow Trevi on <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4397658-1&amp;h=129532414&amp;u=https%3A%2F%2Ftwitter.com%2FTreviThera&amp;a=X\" target=\"_blank\" rel=\"nofollow\">X<\/a>\u00a0(formerly Twitter) and <a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4397658-1&amp;h=2087188226&amp;u=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ftrevi-therapeutics-inc-%2F&amp;a=LinkedIn\" target=\"_blank\" rel=\"nofollow\">LinkedIn<\/a>.<\/p>\n<p>\n        <b>Investor Contact<br \/><\/b><br \/>\n        <span class=\"xn-person\">Jonathan Carlson<\/span><br \/>\n        <br \/>Trevi Therapeutics, Inc.<br \/>(203) 654 3286<br \/><a href=\"mailto:carlsonj@trevitherapeutics.com\" target=\"_blank\" rel=\"nofollow\">carlsonj@trevitherapeutics.com<\/a><\/p>\n<p>\n        <b>Media Contact<br \/><\/b><br \/>\n        <span class=\"xn-person\">Rosalia Scampoli<\/span><br \/>\n        <br \/>914-815-1465<br \/><a href=\"mailto:rscampoli@marketcompr.com\" target=\"_blank\" rel=\"nofollow\">rscampoli@marketcompr.com<\/a><\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=NY56473&amp;sd=2025-04-03\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences-302419110.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences-302419110.html<\/a><\/p>\n<p>SOURCE  Trevi Therapeutics, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=NY56473&amp;Transmission_Id=202504030730PR_NEWS_USPR_____NY56473&amp;DateId=20250403\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire NEW HAVEN, Conn. , April 3, 2025 \/PRNewswire\/ &#8212; Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC),\u00a0today announced that senior management will be participating in the following investor conferences in April. 24th Ann ual Needham Virtual Healthcare Conference April 7-10, 2025 Corporate Presentation: April 7, 11:00-11:40 a.m. ETTrevi Representatives:\u00a0Jennifer Good, President and CEO, and Farrell Simon, CCORegister here to watch the live presentation. Jones Healthcare and Technology Innovation Conference April 8-9, 2025, Las Vegas, Nevada Corporate Presentation: April 9, 11:00-11:20 a.m. PTTrevi Presenter:Jennifer Good, President and CEOPresentation available to in-person attendees. Piper &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Trevi Therapeutics to Participate in Upcoming April Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-833420","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Trevi Therapeutics to Participate in Upcoming April Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trevi Therapeutics to Participate in Upcoming April Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire NEW HAVEN, Conn. , April 3, 2025 \/PRNewswire\/ &#8212; Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC),\u00a0today announced that senior management will be participating in the following investor conferences in April. 24th Ann ual Needham Virtual Healthcare Conference April 7-10, 2025 Corporate Presentation: April 7, 11:00-11:40 a.m. ETTrevi Representatives:\u00a0Jennifer Good, President and CEO, and Farrell Simon, CCORegister here to watch the live presentation. Jones Healthcare and Technology Innovation Conference April 8-9, 2025, Las Vegas, Nevada Corporate Presentation: April 9, 11:00-11:20 a.m. PTTrevi Presenter:Jennifer Good, President and CEOPresentation available to in-person attendees. Piper &hellip; Continue reading &quot;Trevi Therapeutics to Participate in Upcoming April Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-03T11:35:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Trevi Therapeutics to Participate in Upcoming April Investor Conferences\",\"datePublished\":\"2025-04-03T11:35:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\\\/\"},\"wordCount\":551,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1504281\\\/Trevi_Therapeutics_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\\\/\",\"name\":\"Trevi Therapeutics to Participate in Upcoming April Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1504281\\\/Trevi_Therapeutics_Logo.jpg\",\"datePublished\":\"2025-04-03T11:35:46+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1504281\\\/Trevi_Therapeutics_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/1504281\\\/Trevi_Therapeutics_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trevi Therapeutics to Participate in Upcoming April Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Trevi Therapeutics to Participate in Upcoming April Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Trevi Therapeutics to Participate in Upcoming April Investor Conferences - Market Newsdesk","og_description":"PR Newswire NEW HAVEN, Conn. , April 3, 2025 \/PRNewswire\/ &#8212; Trevi Therapeutics, Inc.\u00a0(Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio\u2122 (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC),\u00a0today announced that senior management will be participating in the following investor conferences in April. 24th Ann ual Needham Virtual Healthcare Conference April 7-10, 2025 Corporate Presentation: April 7, 11:00-11:40 a.m. ETTrevi Representatives:\u00a0Jennifer Good, President and CEO, and Farrell Simon, CCORegister here to watch the live presentation. Jones Healthcare and Technology Innovation Conference April 8-9, 2025, Las Vegas, Nevada Corporate Presentation: April 9, 11:00-11:20 a.m. PTTrevi Presenter:Jennifer Good, President and CEOPresentation available to in-person attendees. Piper &hellip; Continue reading \"Trevi Therapeutics to Participate in Upcoming April Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-03T11:35:46+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Trevi Therapeutics to Participate in Upcoming April Investor Conferences","datePublished":"2025-04-03T11:35:46+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/"},"wordCount":551,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/","name":"Trevi Therapeutics to Participate in Upcoming April Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg","datePublished":"2025-04-03T11:35:46+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/1504281\/Trevi_Therapeutics_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/trevi-therapeutics-to-participate-in-upcoming-april-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Trevi Therapeutics to Participate in Upcoming April Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/833420","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=833420"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/833420\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=833420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=833420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=833420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}